These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 24074286)

  • 61. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
    Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
    Zhang X; Yang L; Qiao Z
    Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
    Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q
    PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
    Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
    EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
    Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
    Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
    Park JH; Tallman MS
    Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
    Zhang L; Zhu X; Zou Y; Chen Y; Chen X
    Int J Hematol; 2011 Feb; 93(2):199-205. PubMed ID: 21287409
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer?
    Gill H
    Expert Rev Hematol; 2024 Oct; 17(10):661-667. PubMed ID: 39120131
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
    Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
    Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
    Zhang X; Wu S; Yang J; Zhang G; Su Y; Zhang M; He J; Shi Y; Li W; Lu P; Lu D
    Int J Hematol; 2023 Apr; 117(4):530-537. PubMed ID: 36580227
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
    Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
    Dayyani F; Kantarjian H; O'Brien S; Pierce S; Jones D; Faderl S; Garcia-Manero G; Cortes J; Ravandi F
    Cancer; 2011 Jan; 117(1):110-5. PubMed ID: 20803607
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P
    J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genital vasculitis secondary to all-trans-retinoic-acid.
    Yanamandra U; Khadwal A; Saikia UN; Malhotra P
    BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791116
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
    Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
    Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
    Jaime-Pérez JC; González-Leal XJ; Pinzón-Uresti MA; Gómez-De León A; Cantú-Rodríguez OG; Gutiérrez-Aguirre H; Gómez-Almaguer D
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):816-9. PubMed ID: 26500134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.